Relmada Therapeutics Inc (RLMD) Company Profile & Statistics

Relmada Therapeutics Inc
RLMD
(Nasdaq - US)
N/A
3.75
+0.06 (+1.63%)
in:usd•As of: May 02, 2024 15:59 UTC -4
Open
3.76
High
3.76
Low
3.71

About Relmada Therapeutics Inc

CEO

Sergio Traversa

Headquarters

2222 ponce de leon blvd. 3rd floor

coral gables, fl 33134, united states

Auditor

Marcum LLP

Employees

Share Holders

129

Website

www.relmada.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.

Relmada Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	113.14M
Enterprise Value	109.05M
Enterprise Value/EBITDA (ttm)	-1.05
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.28
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-93.44%
Return on Invested Capital (ttm)	-95.03%
Return on Assets (ttm)	-85.11%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-103.70M
Net Income Avi to Common (ttm)	-98.79M
Diluted EPS (ttm)	-3.28

Share Statistics

Beta (5Y Monthly)	0.27
52-Week Change	37.87%
S&P500 52-Week Change	24.86%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	30.17M
Dividend Yield	0.00%
Float ⁴	24.74M
% Held by Insiders	18.00%
% Held by Institutions	45.24%

Balance Sheet

Total Cash (mrq)	96.32M
Total Cash Per Share (mrq)	3.19
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	8.00%
Quick Ratio (mrq)	8.00%
Book Value Per Share (mrq)	2.84

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.72
Free Cash Flow (ytd)	-51.66M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Relmada Therapeutics Inc

Trade With A Regulated Broker